Drugs / CD19 UCARTcells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04166838 | Nov 2019 | B-cell acute lymphoblastic leukemia | Shanghai Longyao Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07212322 | Jan 2026 → May 2027 expected | Sjogren syndrome, anti-neutrophil cytoplasmic antibody-associated vasculitis, antiphospholipid syndrome, autoimmune thrombocytopenia +3 | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 UCAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07212322 ↗ |
| Modality | Cell therapy | “all the subjects were treated with one single dose of CD19 UCART cells per treatment course” NCT04166838 ↗ |
| Target | CD19 | “CD19 UCAR-T cells treatment” NCT07212322 ↗ |